Can I read Clinical Benefits of Vortioxetine 20 Mg/day in Patients with Major Depressive Disorder on EtoBox?

Clinical Benefits of Vortioxetine 20 Mg/day in Patients with Major Depressive Disorder by Michael C. Christensen; Roger S. McIntyre; Michael Adair; Ioana Florea; Henrik Loft; Andrea Fagiolini is a Medicine article available to read on EtoBox.

What is Clinical Benefits of Vortioxetine 20 Mg/day in Patients with Major Depressive Disorder about?

Abstract Background Vortioxetine has demonstrated dose-dependent efficacy in patients with major depressive disorder (MDD), with the greatest effect observed with vortioxetine 20 mg/day. This analysis further explored the clinical relevance of the more rapid and greater improvement in depressive symptoms observed with vortioxetine 20 mg/day vs 10 mg/day. Methods Analysis of pooled data from six short-term (8-week), randomized, placebo-controlled, fixed-dose studies of vortioxetine 20 mg/day in patients with MDD (N = 2620). Symptomatic response (≥50% decrease in Montgomery–Åsberg Depression Rating Scale [MADRS] total score), sustained symptomatic response, and remission (MADRS total score ≤10) were assessed by vortioxetine dosage (20 or 10 mg/day). Results After 8 weeks, 51.4% of patients receiving vortioxetine 20 mg/day had achieved symptomatic response vs 46.0% of those receiving vortioxetine 10 mg/day (P < .05). Significantly more patients achieved symptomatic response vs placebo from week 2 onwards for vortioxetine 20 mg/day and from week 6 onwards for vortioxetine 10 mg/day (both P ≤ .05). Sustained response was achieved from week 4 for 26.0% of patients receiving vortioxetine

Who reads Clinical Benefits of Vortioxetine 20 Mg/day in Patients with Major Depressive Disorder?

Author

Michael C. Christensen; Roger S. McIntyre; Michael Adair; Ioana Florea; Henrik Loft; Andrea Fagiolini

Publisher

Cambridge University Press (CUP)

Published

2023

Language

EN

Field

Medicine (Health Sciences)